TransIT®-mRNA Transfection Kit

A high efficiency, low toxicity, large RNA transfection reagent for mammalian cells

Each Kit is supplied with the TransIT®-mRNA Transfection Reagent and the mRNA Boost Reagent.

  • Low Cellular Toxicity - Maintain cell density and reduce experimental biases.
  • High Efficiency Delivery - Achieve RNA delivery in a large population of cells to ensure experimental success.
  • Serum Compatible - Perform transfections in the presence of serum which eliminates the need for a media change and maintains cellular health.
  • Deliver Various Sizes of RNA - Ideal for specialized applications, such as viral production and protein expression from mRNA.
mRNA
PLAY
TransIT®-mRNA (1:1:1)
RNAiMAX (4:1)
Stemfect™ (2:1)
 
TransIT-mRNA day 1 TransIT-mRNA day 5 TransIT-mRNA day 9 TransIT-mRNA day 14 TransIT-mRNA day 14 cells
RNAiMax day 1 RNAiMax day 5 RNAiMax day 9 RNAiMax day 14 RNAiMax day 14 cells
Stemfect day 1 Stemfect day 5 Stemfect day 9 Stemfect day 14 Stemfect day 14 cells
Click on the red days to view images
DAILY TRANSFECTIONS
 
 

Figures and Data

Figure 1: High Efficiency and Low Toxicity Transfection Following 14 Consecutive Transfections with TransIT®-mRNA Transfection Kit
Figure 2: The TransIT®-mRNA Transfection Kit Transfects GFP mRNA into DC 2.4 Dendritic Cells
Figure 3: Multiple Dendritic Cell Types Express GFP from mRNA Transfected by TransIT®-mRNA Transfection Kit
Figure 4: High Level Luciferase Expression after Delivery of a Luciferase mRNA using the TransIT®-mRNA Transfection Kit.
Figure 5: The TransIT®-mRNA Transfection Kit Efficiently Delivers the lacZ mRNA to CHO-K1 Cells.
PREVIOUS NEXT
Figure 1:High Efficiency and Low Toxicity Transfection Following 14 Consecutive Transfections with TransIT-mRNA Transfection Kit
Figure 1. High Efficiency and Low Toxicity Transfection Following 14 Consecutive Transfections with TransIT®-mRNA Transfection Kit. Repeated daily transfections were performed in the same population of BJ fibroblasts using TransIT®-mRNA Transfection Kit, Lipofectamine® RNAiMAX (Life Technologies) and Stemfect™ RNA Transfection Kit (Stemgent) - with a capped and polyadenylated EGFP mRNA incorporating pseudouridine and 5mC modified bases (Trilink Biotechnologies, Inc.). Multiple reagent-to-RNA ratios were tested and the optimal ratio is represented. Transfections were performed in 12-well plates using the indicated reagent-to-RNA ratios to deliver 1 µg of RNA. GFP and phase contrast images were taken in the same field of view everyday after transfection. Transfection efficiency was measured by flow cytometry on a Guava easyCyte™ 5HT following 14 consecutive daily transfections (blue bars). Cell viability was determined using cell counts measured during flow cytometry (black line grey bars). Error bars represent the standard deviation of triplicate wells.
Figure 2:The TransIT-mRNA Transfection Kit Transfects GFP mRNA into DC 2.4 Dendritic Cells
Figure 2. The TransIT®-mRNA Transfection Kit Transfects GFP mRNA into DC 2.4 Dendritic Cells. Using TransIT®-mRNA Transfection Kit, DC 2.4 cells were transfected with (A) 0.5 µg, (B) 1 µg and (C) 2.5 µg of capped and polyadenylated mRNA encoding GFP with 1 µl TransIT®-mRNA Reagent and 1 µl Boost. Cells were seeded overnight at 100,000 cells/well in 24-well plates. Images were taken 10 hours post-transfection.

Data courtesy of Kyle Phua (Principal Investigator: Kam W. Leong), Duke University
Figure 3:Multiple Dendritic Cell Types Express GFP from mRNA Transfected by TransIT-mRNA Transfection Kit
Figure 3. Multiple Dendritic Cell Types Express GFP from mRNA Transfected by TransIT®-mRNA Transfection Kit. Murine primary bone marrow derived dendritic cells (BMDC) and murine dendritic cells types (JAWSII and DC 2.4) were transfected with 1 µg of capped and polyadenlyated mRNA encoding GFP using a TransIT®-mRNA Reagent: Boost: mRNA ratio of 1:1:1 (µl:µl:µg). Primary BMDCs, JAWSII and DC 2.4 were seeded (80,000 cell/well) overnight in 24-well plates. Cells were assayed via flow cytometry 8 hours post transfection. Error bars represent the standard deviation of at least 3 separate experiments.

Data courtesy of Kyle Phua (Principal Investigator: Kam W. Leong), Duke University
Figure 4:High Level Luciferase Expression after Delivery of a Luciferase mRNA using  the TransIT-mRNA Transfection Kit.
Figure 4. High Level Luciferase Expression after Delivery of a Luciferase mRNA using the TransIT®-mRNA Transfection Kit. Cells in 12-well plates were transfected with a capped and polyadenylated mRNA encoding luciferase using the TransIT®-mRNA Transfection Kit. Approximately 18 hrs post-transfection the cells were harvested and the total luciferase activity per well was determined.
Figure 5:The TransIT-mRNA Transfection Kit Efficiently Delivers the lacZ mRNA to CHO-K1 Cells.
Figure 5. The TransIT®-mRNA Transfection Kit Efficiently Delivers lacZ mRNA to CHO-K1 Cells. Using the TransIT®-mRNA Transfection Kit, CHO-K1 cells were mock transfected (A) or transfected with a capped and polyadenylated lacZ encoding mRNA (B). Approximately 18 hrs post-transfection the cells were stained using Mirus Bio’s Beta-gal Staining Kit to identify the lacZ transfected cells.
 

Additional Information

NEW! Transfection of Pseudouridine and 5-Methylcytidine Modified Messenger RNA for iPS Cell Reprogramming (pdf)
In Vitro Transcription and Capping of Gaussia Luciferase mRNA Followed by HeLa Cell Transfection. Jani, B., Fuchs, R. J. Vis. Exp. (61), e3702.

Stem Cell Applications
TransIT®-mRNA for high-titer virus production
TransIT®-mRNA Comparison Data to Electroporation and TransMessenger® Reagent
Cell lines successfully transfected at Mirus using TransIT®-mRNA Transfection Kit (pdf)
Close